- Home
- ZYME vs MCRI Comparison
ZYME vs MCRI Comparison
Compare ZYME & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | MCRI |
|---|---|---|
| Founded | 2003 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ZYME | MCRI |
|---|---|---|
| Price | $27.56 | $118.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $38.90 | ★ $111.50 |
| AVG Volume (30 Days) | ★ 504.5K | 131.0K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | 33.33 | ★ 41.41 |
| EPS | N/A | ★ 1.52 |
| Revenue | $105,965,000.00 | ★ $395,377,000.00 |
| Revenue This Year | $183.10 | $4.85 |
| Revenue Next Year | N/A | $2.21 |
| P/E Ratio | ★ N/A | $78.66 |
| Revenue Growth | 38.87 | ★ 114.40 |
| 52 Week Low | $10.89 | $78.34 |
| 52 Week High | $29.75 | $120.63 |
Technical Indicators
Market Signals| Indicator | ZYME | MCRI |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 71.47 |
| Support Level | $22.28 | $89.37 |
| Resistance Level | $28.49 | N/A |
| Average True Range (ATR) | 1.06 | 3.59 |
| MACD | -0.22 | 0.73 |
| Stochastic Oscillator | 39.94 | 88.10 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.